Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.

about

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.

Item

http://www.wikidata.org/entity/Q48341168

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prediction of survival after n ...... es and residual cancer burden.

@en

Prediction of survival after n ...... es and residual cancer burden.

@nl

type

Item

label

Prediction of survival after n ...... es and residual cancer burden.

@en

Prediction of survival after n ...... es and residual cancer burden.

@nl

prefLabel

Prediction of survival after n ...... es and residual cancer burden.

@en

Prediction of survival after n ...... es and residual cancer burden.

@nl

P1476

Prediction of survival after n ...... es and residual cancer burden.

@en

P2093

Hisashi Motomura

http://www.w3.org/2001/XMLSchema#string

Koji Takada

http://www.w3.org/2001/XMLSchema#string

Kosei Hirakawa

http://www.w3.org/2001/XMLSchema#string

Masahiko Ohsawa

http://www.w3.org/2001/XMLSchema#string

Masaichi Ohira

http://www.w3.org/2001/XMLSchema#string

Naoyoshi Onoda

http://www.w3.org/2001/XMLSchema#string

Satoru Noda

http://www.w3.org/2001/XMLSchema#string

Shuhei Tomita

http://www.w3.org/2001/XMLSchema#string

Takaharu Hatano

http://www.w3.org/2001/XMLSchema#string

Tsutomu Takashima

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Preoperative chemotherapy for women with operable breast cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer

Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.

Primary systemic therapy of breast cancer.

P2888

s12885-017-3927-8

P304

888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3927-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Katsuyuki Takahashi

Shinichiro Kashiwagi

P577

2017-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100091461

http://www.w3.org/2001/XMLSchema#string

P698

29282021

http://www.w3.org/2001/XMLSchema#string

P932

5745786

http://www.w3.org/2001/XMLSchema#string